Basic Information
Brintellix
Regulatory Information
EMEA/H/C/002717
Authorised
December 18, 2013
October 24, 2013
24
January 16, 2024
Company Information
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of major depressive episodes in adults.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Brintellix. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Brintellix. For practical information about using Brintellix, patients should read the package leaflet or contact their doctor or pharmacist.